BSE filing, NSE: ZIMLAB. Summary written from the filing by ALFA Finder's alert engine.
Zim Laboratories Ltd: key numbers
- Share price
- ₹138.93
- Market cap
- ₹745.5 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 201.7×Sector 46.1×
- Promoter holding
- 30.30%-0.06% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zim Laboratories Ltd
All →Zim Laboratories Regulatory Approval
Zim Laboratories received TGA GMP certification from Australia's Therapeutic Goods Administration for its Nagpur manufacturing facility. The certification covers various dosage forms and is valid until June 2028.
- From
- Therapeutic Goods Administration (TGA), Australia
Zim Laboratories Credit Rating
CARE Ratings has reaffirmed the credit ratings of Zim Laboratories Limited for its bank facilities, revising the outlook on long-term facilities to negative.
Zim Laboratories Other Announcement
Zim Laboratories Limited filed a certificate confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026.
Zim Laboratories Merger & Restructuring Worth ₹1,404,640 Cr
ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.
- Value
- ₹14,04,640 Cr
Zim Laboratories Merger & Restructuring
ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.
Zim Laboratories Acquisition Worth ₹1.56 Cr
ZIM WOS completed a ₹1.56 Crore investment in stepdown ZIM Scientific Office L.L.C., Dubai, fulfilling the board-approved capital plan. The transaction closes the acquisition announced in August 2025.
- Value
- ₹1.56 Cr
Other board meeting date announcements
All →Natco Pharma Board Meeting Date
Natco Pharma will hold a board meeting on 13 November 2026 to consider unaudited quarterly results and an interim dividend. Trading window closed until 15 November 2026.
Faze Three Board Meeting Date
Faze Three Ltd intimated a board meeting on November 3, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Trading window closure is also noted.
Real Eco-Energy Board Meeting Date
Real Eco-Energy schedules a board meeting on 04 November 2026 for unaudited quarterly results. The trading window stays closed until results are declared.
Arvaya Healthcare Board Meeting Date
Arvaya Healthcare schedules a 4 November 2026 board meeting on rights issue, draft letter of offer and related party transactions. Agenda items remain proposed only.
Prism Johnson Board Meeting Date
Prism Johnson intimated a board meeting on 6 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 2026. The meeting has not yet been held.
Bharat Textiles & Proofing Industries Board Meeting Date
Bharat Textiles & Proofing Industries will hold a board meeting on 05 November 2026 to consider unaudited standalone quarterly and half-year results. Results await approval.